Risk management of risk management: Combining proton pump inhibitors with low-dose aspirin
Harald Vonkeman, Inger Meek, Mart van de Laar
Department of Rheumatology and Clinical Immunology, Arthritis Centre Twente, Medisch Spectrum Twente and University of Twente, Enschede, The Netherlands
Abstract: Low-dose aspirin is widely used in the primary and secondary prevention of cardiovascular events, but is associated with a range of upper gastrointestinal side effects. In this review, we summarize the rationale for low-dose aspirin therapy, quantify the risk for upper gastrointestinal side effects, identify the risk factors involved, and provide an overview of preventive strategies, thereby focusing on the rationale and clinical utility of combining proton-pump inhibitors with low-dose aspirin.
Keywords: low-dose aspirin, gastrointestinal ulcers, Helicobacter pylori, proton-pump inhibitors, H2-receptor antagonists, clopidogrel
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.